University Health Network / Princess Margaret Cancer Centre
Welcome,         Profile    Billing    Logout  
 22 Trials 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Siu, Lillian L
MET4-IO, NCT03686202: Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy

Active, not recruiting
2/3
65
Canada
MET-4
University Health Network, Toronto, NuBiyota
All Solid Tumors
12/24
12/25
INSPIRE, NCT02644369: Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors

Active, not recruiting
2
100
Canada
Pembrolizumab, Keytruda(TM), MK-3475
University Health Network, Toronto, Merck Sharp & Dohme LLC
Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant Melanoma, Advanced Solid Tumors
12/24
12/24
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting
2
720
Canada
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
01/26
01/27
MERIDIAN, NCT05414032: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

Recruiting
2
200
Canada
AZD2936
University Health Network, Toronto, AstraZeneca, NeoGenomics Laboratories
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
07/26
07/26
CAPTIV-8, NCT04273061: Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Recruiting
2
200
Canada
Atezolizumab, TECENTRIQ
British Columbia Cancer Agency, Hoffmann-La Roche
Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer
10/27
10/27
KEYNOTE-A10, NCT03058289: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Checkmark Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Nov 2021 - Nov 2021: Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Completed
1/2
111
Canada, US
INT230-6, anti-PD-1 antibody, pembrolizumab, KEYTRUDA®, MK-3475, anti-CTLA-4 antibody, ipilimumab, Yervoy, BMS-734016
Intensity Therapeutics, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
02/23
02/23
START-001, NCT05592626: A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

Recruiting
1/2
365
Europe, Canada, US
STAR0602
Marengo Therapeutics, Inc.
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
10/26
10/26
NCT02007382: Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction

Recruiting
1
68
US, Canada
Trametinib, GSK1120212
University Health Network, Toronto, National Cancer Institute (NCI)
Solid Tumors, Hepatic Dysfunction
06/15
12/15
NCT03894618: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Completed
1
49
Europe, Canada, US
SL-279252
Shattuck Labs, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
05/23
05/23
NCT02070549: Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Active, not recruiting
1
46
Canada, US
Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
12/24
12/25
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
132
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Recruiting
1
244
Canada, Japan, US, RoW
GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448
GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics
Neoplasms
09/25
09/25
NCI-2021-13901, NCT05172245: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Recruiting
1
46
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasal Cavity Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Locally Advanced Paranasal Sinus Squamous Cell Carcinoma, Locally Advanced Sinonasal Squamous Cell Carcinoma, Maxillary Sinus Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
06/26
06/26
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
PRE-MERIDIAN, NCT04599309: Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma

Active, not recruiting
N/A
35
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada
Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
03/23
12/24
SPECIAL, NCT02724488: Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies

Active, not recruiting
N/A
14
NA
University Health Network, Toronto, Princess Margaret Hospital, Canada
Head and Neck Cancer, Melanoma
12/25
12/25
IRIS, NCT04243720 / 2011-004908-37: Immune Resistance Interrogation Study

Recruiting
N/A
100
Canada
University Health Network, Toronto
Cancer, Solid Tumor, Metastatic Cancer, Immune Resistance
02/25
02/25
COMPARISON, NCT03364621: Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Active, not recruiting
N/A
17
Canada
University Health Network, Toronto, Terry Fox Research Institute, British Columbia Cancer Agency
Colorectal Cancer, Colorectal Cancer Metastatic, Hepatic Metastases
06/25
06/25
LIBERATE, NCT03702309 / 2020-001203-16: Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Recruiting
N/A
2500
Canada
University Health Network, Toronto
Cancer, Breast Cancer, Lung Cancer, Colon Cancer, Ovarian Cancer, Melanoma, Lymphoma, Leukemia, Mutation, Lynch Syndrome, Cowden Syndrome, BRCA1 Mutation, BRCA2 Mutation, Uterine Cancer, Myeloma, Kidney Cancer, Head and Neck Cancer, Meningioma
07/25
07/25
NIP IT!, NCT05196087: Non-Invasive Artificial Intelligence-Based Platform MonIToring Program

Recruiting
N/A
500
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada
Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
06/26
06/26
OCTANE, NCT02906943: Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

Recruiting
N/A
10000
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada
Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gynecological Cancer, Genitourinary Cancer, Pancreatobiliary Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Rare Cancer, Unknown Primary Cancer
08/26
08/26
MOHCCN-O, NCT05403177: Marathon of Hope Cancer Centres Network Study for Ontario

Recruiting
N/A
500
Canada
University Health Network, Toronto, Princess Margaret Hospital, Canada, Ontario Institute for Cancer Research, Terry Fox Research Institute, Queen's University, Kingston, Ontario, Ottawa Hospital Research Institute, Queen's University
Breast Cancer, Colorectal Cancer, Pancreas Cancer, Kidney Cancer, Prostate Cancer, Ovary Cancer, Head and Neck Cancer, Leukemia, Lymphoma, Lung Cancer, Melanoma, Solid Tumor
10/26
10/26
Laskin, Janessa J
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
CAPTIV-8, NCT04273061: Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Recruiting
2
200
Canada
Atezolizumab, TECENTRIQ
British Columbia Cancer Agency, Hoffmann-La Roche
Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer
10/27
10/27
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
NCT02155621: Personalized Oncogenomics (POG) Program of British Columbia

Recruiting
N/A
5000
Canada
Genome sequencing
British Columbia Cancer Agency, BC Cancer Foundation
Metastatic Cancers, Advanced Cancers, Cancers That Cannot be Treated With Curative Intent
12/25
12/25

Download Options